JP6724240B2 - 疾患の処置におけるネクチニブおよびその薬学的に許容可能な塩の新規な使用 - Google Patents
疾患の処置におけるネクチニブおよびその薬学的に許容可能な塩の新規な使用 Download PDFInfo
- Publication number
- JP6724240B2 JP6724240B2 JP2019503742A JP2019503742A JP6724240B2 JP 6724240 B2 JP6724240 B2 JP 6724240B2 JP 2019503742 A JP2019503742 A JP 2019503742A JP 2019503742 A JP2019503742 A JP 2019503742A JP 6724240 B2 JP6724240 B2 JP 6724240B2
- Authority
- JP
- Japan
- Prior art keywords
- gzd824
- cells
- dmso
- mice
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 title description 30
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 20
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 11
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 121
- 210000004027 cell Anatomy 0.000 description 113
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 105
- 241000699670 Mus sp. Species 0.000 description 45
- 210000000952 spleen Anatomy 0.000 description 36
- 230000006907 apoptotic process Effects 0.000 description 32
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 29
- 210000001185 bone marrow Anatomy 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 208000032839 leukemia Diseases 0.000 description 27
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 26
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 26
- 229960002411 imatinib Drugs 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 19
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 17
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 108090000672 Annexin A5 Proteins 0.000 description 15
- 102000004121 Annexin A5 Human genes 0.000 description 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 15
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 15
- 102000001332 SRC Human genes 0.000 description 15
- 238000007619 statistical method Methods 0.000 description 15
- 108060006706 SRC Proteins 0.000 description 13
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 11
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000035519 G0 Phase Effects 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 3
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007730 Akt signaling Effects 0.000 description 2
- -1 BCL-XL Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010039 central nervous system leukemia Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000007696 Proto-Oncogene Proteins c-yes Human genes 0.000 description 1
- 108010021833 Proto-Oncogene Proteins c-yes Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 229940122924 Src inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940127263 dual kinase inhibitor Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
GZD824は、急性リンパ芽球性白血病に対し、特に前駆Bリンパ芽球性白血病に対して、より良い抗腫瘍効果を有する。GZD824は、Pre−B ALL細胞株の増殖を抑制し、そのアポトーシスを誘導し、G0/G1期でPre−B ALL細胞周期を抑制することができる。
実験は、GZD824が、B細胞を死滅させずに、患者由来の初代Pre−B ALL細胞の細胞アポトーシスを促進することができることを示す。
本実施形態は、GZD824がPDXマウスにおいてインビボでPre−B ALL細胞の増殖を抑制することができることを説明する。
本実施形態において、患者の初代pre−B ALLによって構築されたPDXマウスに対する実験的研究は、GZD824がpre−B ALLの移植率を抑制できることを示している。
本実施形態は、GZD824がPre−B ALL細胞のリン酸化されたSRCタンパク質の発現を効果的に抑制することを説明する。
本実施形態は、GZD824がPre−B ALL細胞のPI3K/AKTシグナル経路を効果的に抑制することができることを説明する。
Claims (2)
- 前駆Bリンパ芽球性白血病を処置するための薬剤の製造における、(3−((1H−ピラゾール[3,4−b]ピリジン−5−置換)エチニル)−4−メチル−N−(4−((4−メチルピペラジン−1−置換)メチル)−3−(トリフルオロメチル)フェニル)ベンズアミド)およびその薬学的に許容可能な塩の使用。
- Ph陰性前駆Bリンパ芽球性白血病を処置するための薬剤の製造における、(3−((1H−ピラゾール[3,4−b]ピリジン−5−置換)エチニル)−4−メチル−N−(4−((4−メチルピペラジン−1−置換)メチル)−3−(トリフルオロメチル)フェニル)ベンズアミド)およびその薬学的に許容可能な塩の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610592371 | 2016-07-25 | ||
CN201610592371.2 | 2016-07-25 | ||
CN201611040298.4A CN106580993B (zh) | 2016-07-25 | 2016-11-11 | 耐克替尼及其药学上可接受的盐在治疗疾病中的新的应用 |
CN201611040298.4 | 2016-11-11 | ||
PCT/CN2017/081173 WO2018018950A1 (zh) | 2016-07-25 | 2017-04-20 | 耐克替尼及其药学上可接受的盐在治疗疾病中的新的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019522019A JP2019522019A (ja) | 2019-08-08 |
JP6724240B2 true JP6724240B2 (ja) | 2020-07-15 |
Family
ID=58592880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019503742A Active JP6724240B2 (ja) | 2016-07-25 | 2017-04-20 | 疾患の処置におけるネクチニブおよびその薬学的に許容可能な塩の新規な使用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20200330456A1 (ja) |
EP (1) | EP3488850B1 (ja) |
JP (1) | JP6724240B2 (ja) |
KR (1) | KR20190032425A (ja) |
CN (1) | CN106580993B (ja) |
AU (1) | AU2017303624A1 (ja) |
CA (1) | CA3031852A1 (ja) |
IL (1) | IL264407A (ja) |
MX (1) | MX2019001007A (ja) |
WO (1) | WO2018018950A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111035641B (zh) * | 2018-10-11 | 2022-04-12 | 暨南大学 | Gzd824及其药学上可接受的盐在治疗疾病中的新应用 |
TWI751456B (zh) * | 2018-12-03 | 2022-01-01 | 大陸商蘇州亞盛藥業有限公司 | 癌症療法 |
CN110917157B (zh) * | 2020-01-21 | 2020-06-16 | 上海亚盛医药科技有限公司 | 含炔基化合物的药物组合物、其制备方法及应用 |
US20230078120A1 (en) * | 2020-05-04 | 2023-03-16 | Ascentage Pharma (Suzhou) Co.,Ltd. | Methods for Treating Coronavirus Infections |
CN114533879B (zh) * | 2020-11-19 | 2023-09-29 | 广州顺健生物医药科技有限公司 | 治疗癌症的联合疗法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101885722B (zh) * | 2010-07-01 | 2013-07-24 | 中国科学院广州生物医药与健康研究院 | 杂环炔苯类化合物及其药用组合物和应用 |
US8846671B2 (en) * | 2010-07-01 | 2014-09-30 | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof |
CN103539784B (zh) * | 2012-07-09 | 2016-08-17 | 中国科学院广州生物医药与健康研究院 | 杂环苯甲酰胺类化合物、药用组合物及其应用 |
-
2016
- 2016-11-11 CN CN201611040298.4A patent/CN106580993B/zh active Active
-
2017
- 2017-04-20 AU AU2017303624A patent/AU2017303624A1/en not_active Abandoned
- 2017-04-20 KR KR1020197004252A patent/KR20190032425A/ko not_active Application Discontinuation
- 2017-04-20 JP JP2019503742A patent/JP6724240B2/ja active Active
- 2017-04-20 EP EP17833256.5A patent/EP3488850B1/en active Active
- 2017-04-20 CA CA3031852A patent/CA3031852A1/en not_active Abandoned
- 2017-04-20 MX MX2019001007A patent/MX2019001007A/es unknown
- 2017-04-20 US US16/318,729 patent/US20200330456A1/en not_active Abandoned
- 2017-04-20 WO PCT/CN2017/081173 patent/WO2018018950A1/zh unknown
-
2019
- 2019-01-22 IL IL264407A patent/IL264407A/en unknown
-
2021
- 2021-04-12 US US17/227,841 patent/US20210228573A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3031852A1 (en) | 2018-02-01 |
KR20190032425A (ko) | 2019-03-27 |
JP2019522019A (ja) | 2019-08-08 |
EP3488850A4 (en) | 2020-08-26 |
EP3488850A1 (en) | 2019-05-29 |
CN106580993A (zh) | 2017-04-26 |
CN106580993B (zh) | 2018-11-30 |
US20200330456A1 (en) | 2020-10-22 |
IL264407A (en) | 2019-02-28 |
MX2019001007A (es) | 2019-06-10 |
US20210228573A1 (en) | 2021-07-29 |
AU2017303624A1 (en) | 2019-02-14 |
WO2018018950A1 (zh) | 2018-02-01 |
EP3488850B1 (en) | 2024-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6724240B2 (ja) | 疾患の処置におけるネクチニブおよびその薬学的に許容可能な塩の新規な使用 | |
Liepelt et al. | Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases | |
Yang et al. | Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma | |
Wang et al. | Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma | |
Guan et al. | Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade | |
Wang et al. | Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil | |
Zhuang et al. | Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model | |
CN103845314B (zh) | 一种丹参新酮在制备抗肿瘤药物中的应用 | |
Tao et al. | Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models | |
Song et al. | Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells | |
Xue et al. | Cardamonin inhibits angiogenesis by mTOR downregulation in SKOV3 cells | |
He et al. | CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo | |
Cheng et al. | Fuzheng Huayu inhibits carbon tetrachloride-induced liver fibrosis in mice through activating hepatic NK cells | |
James et al. | TT-301 inhibits microglial activation and improves outcome after central nervous system injury in adult mice | |
Li et al. | Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression | |
Xu et al. | Targeting Tumor Microenvironment: Effects of Chinese Herbal Formulae on Macrophage‐Mediated Lung Cancer in Mice | |
Zhang et al. | Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model | |
Xie et al. | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth | |
CN111035641B (zh) | Gzd824及其药学上可接受的盐在治疗疾病中的新应用 | |
Tan et al. | Erchen Plus Huiyanzhuyu Decoction Inhibits the Growth of Laryngeal Carcinoma in a Mouse Model of Phlegm‐Coagulation‐Blood‐Stasis Syndrome via the STAT3/Cyclin D1 Pathway | |
Liu et al. | Panax notoginseng saponins induce apoptosis in retinoblastoma Y79 cells via the PI3K/AKT signalling pathway | |
Kan et al. | A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells | |
Maji et al. | Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics | |
CN109106715B (zh) | 8-羟基喹啉类药物或其盐在制备用于治疗与brd4相关的疾病的药物中的应用 | |
Yan et al. | Downregulation and subcellular distribution of HER2 involved in MDA-MB-453 breast cancer cell apoptosis induced by lapatinib/celastrol combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200309 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200309 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200601 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200624 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6724240 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |